DOI: 10.1055/s-00034925

Hämostaseologie

Issue 04 · Volume 37 · 2017 DOI: 10.1055/s-007-36432

Editorial

  • 237
    Lindhoff-Last, Edelgard; Scharf, Rüdiger E.:

    Update: Direct oral anticoagulants (DOAC) – their use and clinical management remain a challenge

  • 238
    Scharf, Rüdiger E.:

    Non-factor replacement therapies in hemophilia

  • 238
    Konstantinides, RStavros v.:

    The risiks of interrupting anticoagulation

    • Review

  • 241
    Voigtlaender, Minna; Langer, Florian:

    Direct oral anticoagulants for the treatment of cancer-associated venous thromboembolism

    Behandlung der tumorassoziierten venösen Thromboembolie mit direkten oralen Antikoagulantien
  • 257
    Lindhoff-Last, Edelgard:

    Direct oral anticoagulants (DOAC) – Management of emergency situations

    Management von Notfallsituationen
  • 267
    Koscielny, Jürgen; Rosenthal, Christoph; von Heymann, Christian:

    Update on Direct Oral AntiCoagulants (DOACs)

    Update Direkte Orale AntiKoagulanzien (DOAKs)
  • 277
    Benetos, Georgios; Bonou, Maria; Toutouzas, Konstantinos; Diamantopoulos, Panagiotis; Viniou, Nora; Barbetseas, John:

    Advances in anticoagulation management of patients undergoing cardioversion of nonvalvular atrial fibrillation

    Fortschritte im antikoagulativen Management von Patienten bei Kardioversion eines nichtvalvulären Vorhofflimmerns
  • 286
    Kcükköylü, Seher; Rump, Lars Christian:

    DOAC use in patients with chronic kidney disease

    DOAK bei Patienten mit chronischen Nierenerkrankungen
  • 295
    Gosselin, Robert C.; Douxfils, Jonathan; Adcock, Dorothy:

    Clinical pearls: Laboratory assessments of direct oral anticoagulants (DOACS)

    Laborbeurteilung von direkten oralen Antikoagulanzien (DOAKs)

    • Case Report

  • 302
    Göndör, Gabor; Stöllberger, Claudia:

    Pulmonary embolism four days after interruption of therapy with rivaroxaban

    Pulmonalembolie vier Tage nach Unterbrechung der Therapie mit Rivaroxaban

    • Reviewed & Commented

  • 307
    Tiede, A.:

    Thromboembolic Risks of Non-Factor Replacement Therapies in Hemophilia